Tolerability

Tolerability

Tolerability describes the extent to which patients can withstand the side effects associated with a medication while continuing treatment. It is a critical component of a drug’s overall clinical profile because even a highly efficacious medication has limited utility if patients cannot tolerate it long enough to derive benefit. Tolerability is typically assessed by examining the incidence and severity of adverse events, treatment discontinuation rates, and the need for dose modifications.

In the context of GLP-1 receptor agonist-based therapies, tolerability is closely linked to gastrointestinal adverse events such as nausea, vomiting, and diarrhea. These effects are a pharmacological consequence of GLP-1 receptor activation in the gastrointestinal tract and brainstem, and they tend to be most pronounced during the dose-escalation phase of treatment. Gradual dose titration is the primary strategy for improving tolerability, allowing patients to adapt to increasing drug exposure over several weeks.

In retatrutide clinical trials, gastrointestinal adverse events were the most commonly reported side effects, consistent with the GLP-1 component of the drug’s mechanism. The Phase 2 obesity trial reported treatment discontinuation due to adverse events in approximately 6-16% of participants across active treatment arms, depending on the dose level. These rates are broadly comparable to those observed with other incretin-based therapies, suggesting that the addition of GIP and glucagon receptor agonism does not substantially worsen the tolerability profile.